AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc. (NASDAQ:GH), filed a Form 4 on August 24, 2026, disclosing the sale of 37,500 shares of common stock on August 21, 2026, through the Talasaz Family Foundation.

Key Highlights

  • Reporting person: AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc.
  • Total shares sold: 37,500 shares of common stock disposed of on August 21, 2026, indirectly via the Talasaz Family Foundation.
  • Three separate tranches: 9,023 shares at a weighted average price of $168.1958, 20,888 shares at $169.1618, and 7,589 shares at $170.2862.
  • Price ranges: The three tranches were sold at per-share prices ranging from $167.81 to $168.60, $168.87 to $169.73, and $169.88 to $170.50, respectively.
  • Remaining indirect ownership: Following the transactions, the Talasaz Family Foundation held 37,500 shares of common stock beneficially owned indirectly by the reporting person.
  • Transaction code: All three sales were coded "S" (open-market sale) in the filing.

Talasaz Family Foundation Share Sales Reported in Three Tranches

According to the filing, all three transactions were conducted indirectly through the Talasaz Family Foundation, with the reporting person identified as AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc. The shares involved in each tranche are common stock of the issuer, and all sales occurred on August 21, 2026. The filing does not indicate whether a Rule 10b5-1 plan was in place, as the corresponding checkbox was not selected.

The filing discloses that the prices reported for each tranche represent weighted average sales prices across multiple individual transactions. For the first tranche of 9,023 shares, prices ranged from $167.81 to $168.60, with a weighted average of $168.1958. For the second tranche of 20,888 shares, prices ranged from $168.87 to $169.73, with a weighted average of $169.1618. For the third tranche of 7,589 shares, prices ranged from $169.88 to $170.50, with a weighted average of $170.2862. The filing states that the reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within each range upon request.

Prior to the reported transactions, the Talasaz Family Foundation held 75,000 shares indirectly attributable to the reporting person (calculated from the sequential post-transaction totals of 65,977, 45,089, and 37,500 as disclosed in the filing). No derivative securities transactions were reported. The Form 4 was signed by John G. Saia as attorney-in-fact for AmirAli Talasaz and filed on August 24, 2026.

What Was Disclosed

The filing reported three open-market sales totaling 37,500 shares of Guardant Health common stock on August 21, 2026, all conducted indirectly through the Talasaz Family Foundation, leaving the foundation with 37,500 shares following the transactions.